Clinical trials of 1-beta-D-arabinofuranosyl cytosine and 1,3-bis-(2-chloroethyl)-1-nitrosourea combination in metastatic cancer and acute leukemia.
D000367:Age Factors; D001772:Blood Cell Count; D001792:Blood Platelets; D001806:Blood Urea Nitrogen; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage*; D004357:Drug Synergism; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007275:Injections, Intravenous; D007938:Leukemia / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D009603:Nitroso Compounds / Q000008:administration & dosage*; D009607:Nitrosourea Compounds / Q000009:adverse effects; D012075:Remission, Spontaneous; D012156:Reticulocytes; D012737:Sex Factors; D014508:Urea / Q000008:administration & dosage*; D014527:Uric Acid / Q000097:blood
D006454:Hemoglobins; D009588:Nitrogen Mustard Compounds; D009603:Nitroso Compounds; D009607:Nitrosourea Compounds; D003561:Cytarabine; D014527:Uric Acid; D014508:Urea